Header

UZH-Logo

Maintenance Infos

Smoking status and treatment outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration


Vittorio, Alexander F; Nguyen, Vuong; Barthelmes, Daniel; Arnold, Jennifer J; Cheung, Chui M G; Murray, Neil; Gillies, Mark C (2019). Smoking status and treatment outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. Retina:Epub ahead of print.

Abstract

PURPOSE
To assess whether smoking status affects 1-year visual outcomes in eyes treated with vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.

METHODS
Retrospective analysis of data from a prospectively designed, multicenter, observational database. Nine hundred and eighty seven treatment-naive eyes of patients with neovascular age-related macular degeneration were tracked by the Fight Retinal Blindness! outcome registry in Australia, New Zealand, Singapore, and Switzerland who had documented smoking status at baseline and commenced vascular endothelial growth factor inhibitor therapy from January 2006 to December 2016. Generalized additive models were used to display visual acuity results.

RESULTS
There was a significant difference in mean improvement in visual acuity at 12 months between nonsmokers, ex-smokers, and current smokers (7.7 vs. 6.1 vs. 3.5 letters of change; P = 0.046) among patients who completed 12 months of treatment when adjusted for age, baseline visual acuity, and choroidal neovascular membrane lesion type and nested for practice. There was no significant difference in the median number of injections over 12 months of treatment by smoking status. Current smokers were a mean of 6.2 years younger than nonsmokers when they started treatment (P < 0.001).

CONCLUSION
This study found inferior 12-month visual outcomes in patients who continued to smoke while receiving vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.

Abstract

PURPOSE
To assess whether smoking status affects 1-year visual outcomes in eyes treated with vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.

METHODS
Retrospective analysis of data from a prospectively designed, multicenter, observational database. Nine hundred and eighty seven treatment-naive eyes of patients with neovascular age-related macular degeneration were tracked by the Fight Retinal Blindness! outcome registry in Australia, New Zealand, Singapore, and Switzerland who had documented smoking status at baseline and commenced vascular endothelial growth factor inhibitor therapy from January 2006 to December 2016. Generalized additive models were used to display visual acuity results.

RESULTS
There was a significant difference in mean improvement in visual acuity at 12 months between nonsmokers, ex-smokers, and current smokers (7.7 vs. 6.1 vs. 3.5 letters of change; P = 0.046) among patients who completed 12 months of treatment when adjusted for age, baseline visual acuity, and choroidal neovascular membrane lesion type and nested for practice. There was no significant difference in the median number of injections over 12 months of treatment by smoking status. Current smokers were a mean of 6.2 years younger than nonsmokers when they started treatment (P < 0.001).

CONCLUSION
This study found inferior 12-month visual outcomes in patients who continued to smoke while receiving vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

1 download since deposited on 06 Feb 2020
1 download since 12 months
Detailed statistics

Additional indexing

Contributors:Fight Retinal Blindness! Study Group
Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Ophthalmology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:14 October 2019
Deposited On:06 Feb 2020 16:04
Last Modified:07 Feb 2020 04:15
Publisher:Lippincott Williams & Wilkins
ISSN:0275-004X
OA Status:Closed
Publisher DOI:https://doi.org/10.1097/IAE.0000000000002679
PubMed ID:31613840

Download

Closed Access: Download allowed only for UZH members

Content: Published Version
Language: English
Filetype: PDF - Registered users only until 14 October 2020
Size: 194kB
View at publisher
Embargo till: 2020-10-14